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 Performance of 5-HIAA in Diagnosis 
 The overall sensitivity and specificity of urinary 5-
HIAA in the presence of the carcinoid syndrome is of the 
order of 70 and 90%, respectively  [1, 2] . Midgut carcinoids 
are most liable to produce the carcinoid syndrome with 
5-HIAA elevation, thus attesting to a high specificity 
( 1 90%) in this setting. Fore- and hindgut NETs produce 
less serotonin than midgut tumors  [1, 3] . The sensitivity 
is lower in patients with midgut carcinoid tumors with-
out the carcinoid syndrome. Urinary 5-HIAA levels may 
also depend on tumor volume and may be normal in pa-
tients with non-metastatic carcinoid tumors. Levels may 
be normal even in the presence of the carcinoid syn-
drome, particularly in subjects without diarrhoea; how-
ever, this is a rare event  [4] . In functional midgut tumors, 
discriminating performances may vary depending on 
whether the cut-offs are high or low. Meijer et al.  [1] dem-
onstrated that a low level 5-HIAA cut-off value (2.8 
mmol/mol creatinine) yielded 68% sensitivity and 89% 
specificity, whereas a higher cut-off (6.7 mmol/mol cre-
atinine) improved specificity to 98% at the expense of a 
lower sensitivity (52%). Thus, in order to confidently ex-
clude a carcinoid tumor, a low-level cut-off value may be 
preferred; to confirm the presence of a carcinoid tumor, 
a high-level cut-off value is better. Some patients with the 
 Standards for the Detection and Interpretation of
5-Hydroxyindole Acetic Acid 
 Background/Definition 
 Neuroendocrine tumors (NETs) originating from the 
midgut may result in functional symptoms due to the se-
cretion of various peptides and hormones and most no-
tably 5-hydroxytryptamine (5-HT) or serotonin. This is 
a tryptophan-derived biogenic amine involved in smooth 
muscle contraction, blood pressure regulation and both 
peripheral and central nervous system neurotransmis-
sion. Approximately 2% of dietary tryptophan is convert-
ed into serotonin. Serotonin is synthesized and stored in 
enterochromaffin cells of the gastrointestinal tract (80% 
of total body serotonin content), in dense granules of 
platelets (storage only) and in the serotoninergic neurons 
of the central nervous system. The urinary breakdown 
metabolite of serotonin is 5-hydroxyindole acetic acid (5-
HIAA) which is particularly useful in the diagnosis and 
follow-up of NETs with carcinoid syndrome. Serum mea-
surements of serotonin are possible in these patients; 
however, large individual variation makes them unreli-
able for diagnosis and in follow-up. Universally, 5-HIAA 
is the most frequently performed assay in the clinical set-
ting of the carcinoid syndrome.
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carcinoid syndrome excrete non-hydroxylated indole ac-
ids, not measured as 5-HIAA. There appears to be an in-
constant correlation between 5-HIAA level and the clin-
ical severity of the carcinoid syndrome; this may be re-
lated to a fluctuating release of serotonin from tumors 
such that the correlation may not be reliable. Recent data 
have examined 5-HIAA as a prognostic factor in these 
patients: while interesting data have emerged, the expert 
group felt that data have not confirmed 5-HIAA levels to 
be a  consistently reliable  prognostic  factor in this disease. 
To illustrate this, two studies including 256 and 139 pa-
tients with midgut carcinoid tumors showed that while 
elevated 5-HIAA levels were predictive of poor outcome 
at univariate analysis, this did not remain significant at 
multivariate analysis  [5, 6] . In another study examining 
76 patients, those with persistent moderately  increased 
urinary 5-HIAA levels ( ^  20 mmol/mol creatinine) had 
a more favourable outcome compared to those with great-
ly elevated levels  [7] . A further study in a mixed tumor 
group including 119 patients (53 of midgut origin) inter-
estingly found high 5-HIAA to be an independent sur-
vival factor  [8] .
 Assays for 5-HIAA 
 While several assays are available to measure 5-HIAA 
(thin-layer chromatography, enzyme immunoassay, gas 
chromatography, gas chromatography-mass spectrome-
try)  [9–12] , the use of high-performance liquid chroma-
tography (HPLC) is most frequently employed. HPLC 
with electrochemical detection is currently recommend-
ed; however, automated assays  [13] or those using mass 
spectrometry  [12] may be available in some laboratories. 
Liquid chromatography tandem mass spectrometry as-
say appears to be a rapid assay with little necessity for 
repeat analyses because of chromatographic interference 
or dilutions  [12] . A further automated method with on-
line solid-phase extraction and HPLC and fluorometric 
detection has recently been shown to have increased pre-
cision and faster throughput compared to the manual sol-
vent extraction method  [14] . Whatever technique is used, 
it should be performed in accredited laboratories.
 Conditions for Optimal Assay  ( fig. 1 ) 
 Urine should be collected and measured in plastic 
containers. Acid should be added to ensure sterility and 
hence stability. The sample should be stored in a refrig-
erator until analysis. All the urine passed over 24 h should 
be collected into the container, preferably by using a mea-
suring jug. Collecting should be started at a defined time 
point following urination, and after that urine should be 
collected until the same time point the next day (a precise 
24-hour collection). Written instructions should be 
 handed out including food and medication precautions 
( fig. 1 ).
 Care in Interpreting 5-HIAA Levels 
 Intraindividual variation of 5-HIAA is also possible 
and this variation may be high, therefore two consecutive 
24-hour collections should be performed and the mean 
value of these two can be taken, especially when the col-
lection is required for diagnosis. A single specimen may 
be sufficient for follow-up purposes. Certain co-morbid-
ities or associated disorders may have effects on the con-
centration of 5-HIAA. Falsely low 5-HIAA levels may be 
encountered in patients with renal impairment and those 
on haemodialysis. In addition, 5-HIAA may be increased 
in untreated patients with malabsorption, who have in-
creased urinary tryptophan metabolites. Such patients 
include those with gluten-sensitive enteropathy (coeliac 
disease), tropical sprue, Whipple disease, intestinal stasis 
and cystic fibrosis (chronic intestinal obstruction)  [1, 15] ; 
plasma 5-HT, but not urinary 5-HIAA, have been elevat-
ed in diarrhoea-predominant irritable bowel syndrome 
 [16] . A small number of normal individuals may have el-
evated urinary 5-HIAA and therefore other objective 
findings should be used in conjunction with tumor mark-
er analysis to support the diagnosis of a carcinoid  [17] . 
The following food substances are rich in dietary trypto-
phan and therefore patients should abstain from these for 
3 days prior to urinary collection: plums, pineapples, ba-
U On day 1, urinate into the container upon rising in the 
morning.
U Collect all subsequent urine for the next 24 h.
U On day 2, urinate into the container upon rising in the 
morning.
U Keep the sample in the refrigerator or a cool place during 
the collection period. Upon completion, return it as in-
structed as soon as possible.
Some foods contain high levels of serotonin which may increase 
the levels of urinary 5-HIAA and consumption should be avoided 
3 days prior to urine collection: plums, pineapples, bananas, egg-
plants, tomatoes, avocados, and walnuts.
Certain medications may also interfere with the assay. If on med-
ications this should be discussed with your specialist physician 
who will give further advice.
 Fig. 1. Procedure for collection of a 24-hour urine sample. 
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nanas, eggplants (aubergines), tomatoes, avocados and 
walnuts  [2, 18, 19] . Certain medications may increase or 
decrease 5-HIAA urinary levels as follows:
 – Increased: acetanilide, phenacetin, glyceryl guaiaco-
late (found in many cough syrups), methocarbamol, 
and reserpine, cisplatin, fluorouracil, melphalan, rau-
wolfia. 
 – Decreased: chlorpromazine, heparin, imipramine, 
isoniazid, levodopa, monoamine oxidase inhibitors, 
methenamine, methyldopa, phenothiazines, prometh-
azine, and tricyclic antidepressants, chlorophenylala-
nine, corticotrophin, guanfacine, imipramine, isocar-
boxazid, isoniazid, levodopa, MAO inhibitors, mo-
clobemide, octreotide. 
 Patients are frequently treated with somatostatin ana-
logues and these are known to decrease levels of 5-HIAA; 
where possible, assays for  diagnostic purposes should be 
made in patients not on somatostatin analogues, while in 
the  follow-up setting, comparisons should be performed 
in patients on stable or comparable doses.
 Insulinoma: 72-Hour Fast 
 NETs secreting insulin are termed insulinomas and 
are almost exclusively intrapancreatic in nature. Exces-
sive insulin secretion leading to hypoglycaemia usually 
results in a combination of neurologic (diplopia, blurred 
vision, confusion, abnormal behavior and amnesia, sei-
zures, coma, etc.) and autonomic (sweating, weakness, 
hunger, tremor, nausea, feelings of warmth, anxiety, pal-
pitations) symptoms. Symptoms are usually related to the 
degree of insulin-induced hypoglycaemia but may be 
non-specific. Hypoglycaemia-induced clinical signs are 
classically present in the early morning preprandial phase 
or may be exercise-induced. The diagnosis is suggested in 
the presence of: (1) symptoms of hypoglycaemia; (2) glu-
cose  ! 2.2 mmol/l (40 mg/dl; others use a threshold of  ! 3 
mmol/l, 50 mg/dl), and (3) relief of symptoms with ad-
ministration of glucose  [20] . This is known as Whipple’s 
triad. The 72-hour fast is the gold standard for diagnos-
ing insulinoma and relates to the integrity of patients’ 
endogenous suppression of insulin in the face of hypogly-
caemia. The fast attests to autonomous insulin secretion 
and the failure of appropriate insulin suppression in the 
presence of hypoglycaemia. Factitious hypoglycaemia 
secondary to exogenous use of insulin is suspected on the 
finding of high (often very high) serum insulin in com-
bination with suppression of C-peptide. Sulphonylureas 
and related insulin secretagogues result in a clinical pic-
ture similar to patients with insulinoma and may be di-
agnosed by a positive drug screen  [21] . An overall ap-
proach to diagnosing and managing insulinoma has been 
provided elsewhere in a recent consensus statement  [22] .
 Supervised 72-Hour Fast 
 This test has been verified as the gold standard in estab-
lishing a biochemical diagnosis of insulinoma  [23] . Pa-
tients should be hospitalized in a specialist unit experi-
enced in performing the test. A 72-hour period is univer-
sally recognized as the most appropriate duration  [22] 
although some groups have proposed a shorter fast of 48 h 
 [24, 25] . Symptoms appear within 12 h for one third of pa-
tients, 80% within 24 h, 90% with 48 h and approaching 
100% within 72 h  [26] . Absolute values of glucose and in-
sulin are the most important variables and any measurable 
insulin is abnormal when blood glucose drops to 2.5
mol/l (45 mg/dl). Assays used for the determination of in-
sulin, pro-insulin, C-peptide and   -hydroxybutyrate may 
vary but should be performed in accredited laboratories. 
Very occasionally, an insulinoma is only revealed by hypo-
glycaemia induced by a mixed meal rather than fasting.
 Patient Information Scheme 
 A detailed description of the fast should be provided 
to all patients with an information card to help in symp-
tom identification. Patients should stay off all foods ex-
cept for plain water, black tea or coffee and essential med-
ications (particularly hypoglycaemic agents, e.g., sulpho-
nylureas).
 Procedure 
 The timing of the 72-hour fast is not critical – some 
teams prefer to perform the test early in the week when 
staffing levels may be higher and avoiding prolonging the 
test into the weekend. An oral glucose tolerance or mixed 
meal test can be performed before the fast. The patient 
should be monitored in a supervised environment and 
fasting should be accompanied by an intravenous line.
 – Absolute blood (venous) determinations should be 
performed at least 2–4 times per day and when the
patient describes symptoms. The test interpretation 
should be made using laboratory blood glucose assays; 
bedside measurements can be used in the presence of 
clinical symptoms to determine if more definitive 
measurements should be made. 
 – Blood should also be drawn for insulin measurement 
concurrently with glucose estimations, and assay for 
insulin and C-peptide when the hypoglycaemia is 
confirmed. 
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 –   -Hydroxybutyrate (or urinary ketones) should be 
measured at the end of the test in order to confirm the 
validity of the fast. A low level of hydroxybutyrate in 
the presence of hypoglycaemia confirms inappropri-
ate insulin or insulin-like hormone secretion. 
 – A urinary assay for sulphonylureas should be per-
formed as a specific request. 
 • Not all drugs are detected, e.g. repaglinide  [21] ; 
false positive results may also occur, e.g. on para-
cetamol. 
 • The results need to be confirmed with the local lab-
oratory. 
 Definition of Hypoglycaemia 
 The endpoint of the test is documented hypoglycae-
mia.
 – Documented blood glucose levels  ^  2.2 mmol/l ( ^  40 
mg/dl; according to some  ! 3 nmol/l, 50 mg/dl; levels 
may depend on age and sex); 
 – Concomitant insulin levels  1 6   U/l ( 6 36 pmol/l;  6 3 
  U/l by ICMA); 
 – A   -hydroxybutyrate level  ^  2.7 mmol/l can be used 
as a surrogate marker to confirm the validity of the fast 
and inappropriate insulin suppression; 
 – A glucagon test immediately after 72-hour fasting in 
patients without definite results has also been recom-
mended; 
 – Exercise test immediately after 72-hour fasting in pa-
tients without definitive results may be performed in 
a supervised setting; 
 – Use of a ratio of insulin to glucose to aid in the diag-
nosis is not recommended. 
 Standards for the Diagnosis of a Gastrinoma: 
Secretin Test 
 The diagnosis of Zollinger-Ellison syndrome (ZES) 
can be established by the demonstration of elevated fast-
ing serum gastrin (FSG) in the presence of low gastric pH. 
FSG alone is not adequate to make the diagnosis of ZES 
because hypergastrinaemia can be seen in patients with 
achlorhydria associated with chronic atrophic fundus 
gastritis (e.g., pernicious anaemia) and in other condi-
tions with hyperchlorhydria (e.g.,  Helicobacter pylori  in-
fection, gastric outlet obstruction, renal failure, antral G-
cell syndromes, short bowel syndrome, retained antrum). 
In addition, the use of chronic proton pump inhibitors 
(PPIs) leads to high FSG levels and therefore gastrin pro-
vocative tests are needed to establish the diagnosis of 
ZES. Indeed, in a recent prospective analysis, up to two-
thirds of gastrinoma patients were found to have FSG val-
ues  ! 10-fold normal  [27] . The gold standard is the secre-
tin test  [27–31] . This hormone, when given intravenously 
provokes an increase in serum gastrin and secondarily in 
gastric acid secretion. The most reliable data concerning 
the secretin test have emanated from the National Insti-
tute of Health studies in patients with sporadic and mul-
tiple endocrine neoplasia type-I (MEN1)-associated gas-
trinomas  [27–31] . Recent consensus guidelines have de-
scribed the criteria used for establishing the diagnosis of 
gastrinoma  [31] ; however, according to the expert com-
mittee, acid output studies are available to only a limited 
number of groups (including those experts’ groups). For 
the NIH group the secretin test was useful in diagnosing 
ZES regardless of the extent or locations of the tumor, the 
presence or absence of MEN1 or the level of FSG (less 
than or greater than 1,000 pg/ml)  [28] . In patients with 
fasting gastrin  ! 1,000 pg/ml, the sensitivity of the secre-
tin test using the criterion delta (increase from prestimu-
lation level) gastrin of  6 110 pg/ml was 93% (CI 76–99%) 
and for a delta gastrin of 200 pg/ml sensitivity was 85% 
(CI 66–96%) (p  1 0.05)  [28] . The same group recently re-
ported their prospective experience on gastrin provoca-
tive tests in 293 patients from the NIH with ZES and com-
pared with 537 ZES patients in the literature and 462 non-
ZES patients (again from the literature)  [30] . This group 
established a delta gastrin of  6 120 pg/ml in patients with 
 ! 10-fold increase as having the highest sensitivity and 
specificity (94 and 100%, respectively)  [30] . They also 
demonstrated the clear superiority of the secretin provo-
cation test compared to the calcium test (94 vs. 62%). 
However, in ZES patients with a negative secretin test the 
calcium provocation test may be helpful  [30] . The expert 
group noted that certain groups had difficulty in obtain-
ing secretin, hindering accurate diagnosis.
 Indications for Gastrin Provocative Tests: Secretin Test 
 – The secretin test is performed to confirm a biochemi-
cal diagnosis of gastrinoma. The test may be repeated 
during the follow-up after curative surgery. FSG should 
be performed prior to secretin test; if FSG  1 1,000 pg/
ml a secretin test is not necessary. When FSG lies be-
tween 200 and 1,000 pg/ml, a secretin test should be 
performed; 
 – The following conditions should also be document-
ed: 
 ] Absence of fundic atrophic gastritis 
  • Antral and fundic biopsies ( 8 serology for anti-
parietal and intrinsic factor antibodies); 
 O’Toole /Grossman/Gross /Delle Fave/
Barkmanova /O’Connor  /Pape /Plöckinger 
Neuroendocrinology 2009;90:194–202198
  • 24-hour pH-metry (loss of diurnal pH course); 
basal acid output is recommended pre and post 
secretin where possible; BAO  1 15 mmol/h is 
highly suggestive of diagnosis of ZES; a random 
pH analysis during upper gastrointestinal en-
doscopy was also suggested (this requires fur-
ther evaluation); 
  •  Helicobacter pylori  testing; 
 ] Other conditions leading to high FSG should be 
considered, including: gastric outlet obstruction, 
renal failure, antral G-cell syndromes, short bowel 
syndrome, retained gastric antrum. 
 Preparation for Secretin Test 
 – If possible, PPIs should be interrupted 10 days to 2 
weeks prior to the test (PPIs for 2 weeks can be re-
placed by H 2 blockers); interruption of H 2 blockers for 
approximately 48 h prior to test, however, interruption 
of all anti-secretory medications should be individu-
ally adapted and patients should be warned of re-ap-
parition of symptoms and should have sufficient anti-
secretory medications to start should they become 
symptomatic; certain patients may have to be hospital-
ized during anti-secretory therapy withdrawal; 
 – Heparinized vacutainers are used and should be la-
beled and placed in ice. 
 Secretin Test 
 – Patient fasting overnight, 12–14 h. 
 – Site indwelling i.v. cannula. 
 – Kabi-secretin (2 U/kg body weight) is given by intra-
venous bolus. 
 – Serum gastrin  
 ] baseline measured at –15, and –1 min before test; 
 ] 2, 5, 10, 15, 20, and 30 min after secretin. 
 – Samples stored on ice ( immediate transfer to labora-
tory). 
 Possible side effects of the secretin test include flush, 
allergic reaction .
 Interpretation of Results 
 – Delta gastrin at least 200 pg/ml any time during the 
test is considered as positive.  
 – The NIH has recently published a delta gastrin of 
 6 120 pg/ml as having a high sensitivity and specific-
ity (94 and 100%, respectively)  [30] . 
 Serum Chromogranin A 
 Chromogranin A (CgA) is an acid glycoprotein with 
439 amino acids that is present in the secretory dense core 
granules of most neuroendocrine cells  [32] . The chromo-
granin family consists of at least three different water-
soluble acidic glycoproteins (CgA, CgB, and secreto-
granin II, sometimes called chromogranin C). Upon 
stimulation, CgA and other peptide hormones and neu-
ropeptides are released. CgA is also secreted from neuro-
endocrine-derived tumors including foregut, midgut and 
hindgut gastrointestinal NETs, pheochromocytomas, 
neuroblastomas, medullary thyroid carcinomas, some 
pituitary tumors, functioning and non-functioning pan-
creatic NETs and other amine precursor uptake and de-
carboxylation tumors. CgA has also been widely used as 
an immunohistochemical marker in NETs  [33] and is rec-
ognized as the most effective. CgA has been recognized 
as a general serum marker, as it is co-secreted in tumors 
with the amines and peptides that are present in the neu-
rosecretory granules  [34] and can be elevated in both 
functionally active and non-functional NETs. Specificity 
of elevated CgA is related to tumor type and is almost 
universally elevated in patients with gastrinoma  [35–37] . 
It is often high in NETs from midgut origin and non-
functioning pancreatic NETs. Differences in tumor cell 
type, histological differentiation and tumor volume may 
influence the level of CgA and interpretation may also 
depend on the assay used in measurement.
 Reliability of CgA in Patients with NETs 
 Overall CgA has been found to be clinically informa-
tive and moderately sensitive in the majority of studies 
devoted to this topic. CgA was found to be more sensitive 
than neurone-specific enolase in all subgroups of a large 
mixed NET patient cohort (n = 128)  [38] . While perfor-
mances have been limited in low-level cut-offs due to the 
overlap with control populations, very high levels of se-
rum CgA are rarely found outside the setting of NETs 
with the exception of patients on gastric acid secretory 
blockers, especially PPIs (see below)  [39] or those with 
hypergastrinaemia. Specificity of CgA in the diagnosis of 
NETs depends on the tumor type and burden (100% spec-
ificities have been reported in patients with metastatic 
disease  [40–43] ), the quality of the control populations 
used and the cut-off values employed  [36, 44] . Elevated 
CgA was found to be more sensitive than high urinary 5-
HIAA levels in patients with metastatic midgut lesions 
(87 vs. 76%, respectively)  [5] . Nobels et al.  [35] demon-
strated a significant positive relation between the serum 
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levels of CgA and the tumor mass in NETs; however, the 
distinction between high and low tumor volume may be 
open to question. This study also confirmed tissue speci-
ficities as high CgA concentrations were found in all pa-
tients with gastrinoma, although small in size and tumor 
volume  [35] . In a mixed series of 128 patients with NET, 
increased CgA levels were found in 29 and 67% of patients 
with locoregional or metastatic disease, respectively  [38] . 
Nonetheless, the prognostic value of CgA in patients with 
NET has not been confirmed to date.
 False-positive elevation of CgA may occur in the fol-
lowing circumstances: 
 – Impaired renal function  [45, 46] ; 
 – Parkinson disease, untreated hypertension and preg-
nancy; 
 – Steroid treatment or glucocorticoid excess, which can 
lead to up-regulation of CgA mRNA  [47, 48] ; 
 – Chronic atrophic gastritis (type A)  [49] ; 
 – Treatment with anti-secretory medications, especially 
PPIs  [39] . 
 Chronic elevation of gastrin levels provokes hyperpla-
sia of the neuroendocrine cells of the stomach, and these 
cells are able to secrete CgA  [50] . In patients with chron-
ically elevated CgA and ZES, Stabile et al.  [51] demon-
strated that the CgA concentrations can be normalized 
by gastrectomy alone, without resection of the gastrin-
producing tumor. A more recently described case report 
of false-positive CgA was due to the presence of hetero-
phile antibodies (HAb), which can bind to animal anti-
gens and may be present in up to 40% of the normal pop-
ulation  [52] ; in the CgA immunometric assays, HAb 
 interferences may be circumnavigated by using a HAb-
blocking tube  [53] .
 Assays for CgA 
 A recognized international standard for CgA assay is 
not available and variations in assay types may influence 
results. Several assays for measurements of intact CgA 
and cleavage products have been developed  [34, 54] . The 
complexity of assays is explained by the presence of sev-
eral CgA-related peptides from human and other species 
 [55] and CgA processing varies according to neuroendo-
crine cells/tissue  [56, 57] . A competitive radioimmuno-
assay can detect circulating CgA, with the use of purified 
full-length human CgA  [41, 58] . Commercial CgA kits 
differ in the types of antibodies used (monoclonal vs. 
polyclonal) and include enzyme detection (ELISA) and 
radioimmunoassay. Differences in methods of standard-
ization have also led to heterogeneity. Generally, mea-
surement of intact CgA in plasma has greater sensitivity 
for the diagnosis of NET than the measurement of frag-
ments  [34, 59] . Stridsberg et al.  [44] compared the three 
commercially available kits in a group of NET patients 
and found sensitivities to vary between 67 and 93%, 
while specificities were  1 85% for all three. A recent mul-
ticentre prospective comparison between two methods, 
immunoradiometric and ELISA, found a 36% clinical 
discordance rate  [60] . These results were mirrored with 
a difference of 5-fold inter-laboratory variation rate in a 
recent Italian study aimed at assessing CgA detection 
performance as applied to immunoradiometric and ELI-
SA assays  [61] . A further prospective analysis underlined 
CgA to be a practical marker in patients with NET, how-
ever, with limited diagnostic power; using RCO curves, 
a cut-off of 53 ng/ml for IRMA and 16 U/l for ELISA for 
discriminating between healthy controls and NET pa-
tients yielded only moderate sensitivities (71.3 and 83%, 
respectively) and specificities (71 and 85%, respectively) 
 [43] .
General Remarks on CgA
– CgA is the most practical and useful general serum tu-
mor marker in patients with NET;
– Elevated CgA can occur in normal individuals and in 
patients with non-NET tumors although the levels are 
usually lower than in patients with NET;
– Sensitivity of elevated CgA varies according to NET tu-
mor type and volume.
CgA Assays and Interpretation
– Reference laboratories should be preferred for clinical 
samples assays;
– Reference intervals and individual patient results differ 
significantly between different chromogranin A assays 
and cannot be directly compared;
– Serial measurements should be performed using the 
same assay;
– If assays are changed, patients should undergo a new 
baseline measurement;
– False-positive results are possible in patients with hy-
pergastrinaemia (especially on anti-secretory medica-
tions or chronic atrophic gastritis type A) and in the 
presence of heterophile antibodies (care in patients au-
toimmune disease or those sensitized to rodent proteins 
(mouse monoclonal antibodies));
– Where possible, proton pump inhibitors should be in-
terrupted, leaving a clearance of at least 3 half-lives, pri-
or to CgA plasma sampling.
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